Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Non Operating Income (2018 - 2025)

Serina Therapeutics (SER) has disclosed Non Operating Income for 8 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 265.98% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 3222.37% year-over-year, with the annual reading at $4.8 million for FY2025, 2016.23% up from the prior year.
  • Non Operating Income hit $4.7 million in Q4 2025 for Serina Therapeutics, up from $1.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $9.0 million in Q2 2024 to a low of -$12.7 million in Q1 2024.
  • Historically, Non Operating Income has averaged $840300.0 across 5 years, with a median of $86500.0 in 2023.
  • Biggest five-year swings in Non Operating Income: surged 8640.0% in 2021 and later plummeted 25775.0% in 2022.
  • Year by year, Non Operating Income stood at -$292000.0 in 2021, then plummeted by 235.27% to -$979000.0 in 2022, then skyrocketed by 938.0% to $8.2 million in 2023, then tumbled by 134.32% to -$2.8 million in 2024, then surged by 265.98% to $4.7 million in 2025.
  • Business Quant data shows Non Operating Income for SER at $4.7 million in Q4 2025, $1.8 million in Q3 2025, and $68000.0 in Q2 2025.